Complement Component 3 (C3) Recombinant Protein | C3 recombinant protein

Recombinant Complement Component 3 (C3)

Cat. Num. AAA2012108

• Applications: SDS-Page, Western Blot, ELISA, Immunoprecipitation
• Purity: > 95%
• Synonyms: Complement Component 3 (C3); Recombinant Complement Component 3 (C3); C3 recombinant protein

• Host: E Coli
• Purity/Purification: > 95%
• Form/Format: Supplied as lyophilized form in PBS,pH7.4, containing 5% sucrose, 0.01% sarcosyl.
• Sequence: The target protein is fused with N-terminal His-Tag, its sequence is listed below.; MGHHHHHHSGS-DLSDQ VPDTDSETRI LLQGTPVAQM AEDAVDGERL KHLIVTPSGC GEQNMIGMTP TVIAVHYLDQ TEQWEKFGLE KRQEALELIK KGYTQQLAFK QPISAYAAFN NRPPSTWLTA MWSRSFSLAA NLIAIDSQVL CGAVKWLILE KQKPDGVFQE DGPVIHQEMI GGFRNTKEAD VSLTAFVLIA LQEARDICEG QVNSLPGSIN KAGEYLEASY LNLQRPYTVA IAGYALALMN KLEEPYLTKF LNTAKDRNRW EEPGQQLYNV EATSYALLAL LLLKDFDSVP PVVRWLNDER YYGGGYGSTQ ATFMVFQALA QYRADVPDHK DLNMDVSLHL PSRSSPTVFR LLW
• Sequence Length: 1663

• Applicable Applications for C3 recombinant protein: SDS-PAGE, Western Blot (WB), ELISA (EIA), Immunoprecipitation (IP)
• Organism: Rattus norvegicus (Rat)
• Expression System: Prokaryotic expression
• Residues: Asp966~Trp1313 (Accession # P01026) with N-terminal His-Tag
• Endotoxin Level: <1.0EU per 1ug (determined by the LAL method)
• Reconstitution: Reconstitute in sterile PBS, pH7.2-pH7.4.
• Preparation and Storage: Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months.; Stability Test: The thermal stability is described by the loss rate of the targetprotein. The loss rate was determined by accelerated thermal degradation test,that is, incubate the protein at 37 degree C for 48h, and no obvious degradation andprecipitation were observed. (Referring from China Biological Products Standard,which was calculated by the Arrhenius equation.) The loss of this protein is lessthan 5% within the expiration date under appropriate storage condition.

SDS-Page

NCBI and Uniprot Product Information

• NCBI GI #: 158138561
• NCBI GeneID: 24232
• NCBI Accession #: NP_058690.2
• NCBI GenBank Nucleotide #: NM_016994.2
• UniProt Accession #: P01026; Q9ET19; Q9QV57; Q9QV58
• Molecular Weight: 40.3kDa
• NCBI Official Full Name: complement C3
• NCBI Official Synonym Full Names: complement component 3
• NCBI Official Symbol: C3
• NCBI Protein Information: complement C3
• UniProt Protein Name: Complement C3
• Protein Family: Complement C3
• UniProt Gene Name: C3
• UniProt Synonym Gene Names: ASP
• UniProt Entry Name: CO3_RAT

NCBI Description

putative complement component C3; likely involved in innate immune response [RGD, Feb 2006]

Uniprot Description

C3: C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. Defects in C3 are the cause of complement component 3 deficiency (C3D). A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis. Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9). ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin- containing structure known as Bruch membrane. Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5). An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage.

Protein type: Secreted, signal peptide; Secreted; Inhibitor

Cellular Component: extracellular space

Molecular Function: protein binding; endopeptidase inhibitor activity; cofactor binding; C5L2 anaphylatoxin chemotactic receptor binding; lipid binding

Biological Process: positive regulation of developmental growth; response to glucocorticoid stimulus; complement activation, alternative pathway; fatty acid metabolic process; chemotaxis; response to estradiol stimulus; tolerance induction; complement activation; positive regulation of angiogenesis; response to magnesium ion; positive regulation of activation of membrane attack complex; response to estrogen stimulus; positive regulation of type IIa hypersensitivity; positive regulation of G-protein coupled receptor protein signaling pathway; positive regulation of phagocytosis; positive regulation of protein amino acid phosphorylation; blood coagulation; response to progesterone stimulus; inflammatory response; complement activation, classical pathway